2'-O-pentyluridine | 160527-03-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 2'-O-pentyluridine
• 英文别名: 1-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-pentoxyoxolan-2-yl]pyrimidine-2,4-dione
• CAS: 160527-03-7
• 化学式: C₁₄H₂₂N₂O₆
• 分子量: 314.338
• InChiKey: CZOMRANVTBYOHH-OJAKKHQRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  [[(2S,3R,4R,5R)-3-butoxy-4-butyl-5-(2,4-dioxopyrimidin-1-yl)-4-hydroxyoxolan-2-yl]-hydroxymethylidene]tin 、 1-溴戊烷 、 碘化钠 、 在 silica gel 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2'-O-pentyluridine
  参考文献：
  名称：

  2'-O-modified nucleosides and phosphoramidites

  摘要：

  2'-O-修饰核苷、核苷酸和寡核苷酸。这些2'-O修饰的寡核苷酸能够抵抗核酸酶消化，能够有效地与互补的多核苷酸杂交。

  公开号：

  US05914396A1

文献信息

• Process for the preparation of 2'-O-alkyl purine phosphoramidites
  申请人：Isis Pharmceuticals, Inc.

  公开号：US05646265A1

  公开（公告）日：1997-07-08

  2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites are prepared by alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. Alkylation is effected on 2,6-diamino-9-(.beta.-D-ribofuranosyl)purine followed by deamination to prepare guanosine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected on a dialkyl stannylene derivative of uridine to prepare uridine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on cytidine to prepare cytidine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on 2,6-diaminopurine to prepare 2,6-diaminopurine 2'-O-alkylated 3'-O-phosphormidites.

  2'-O-烷基化鸟嘌呤、尿苷、胞苷和2,6-二氨基嘌呤3'-O-磷酰胺酯是通过烷基化核苷前体、加入适当的阻断基和磷酸化制备的。烷基化作用在2,6-二氨基-9-(β-D-核糖呋喃基)嘌呤上进行，然后进行去氨作用以制备鸟嘌呤2'-O-烷基化3'-O-磷酸酰胺酯。烷基化作用在尿苷的二烷基锡衍生物上进行，以制备尿苷2'-O-烷基化3'-O-磷酸酰胺酯。烷基化作用直接在胞苷上进行，以制备胞苷2'-O-烷基化3'-O-磷酸酰胺酯。烷基化作用直接在2,6-二氨基嘌呤上进行，以制备2,6-二氨基嘌呤2'-O-烷基化3'-O-磷酸酰胺酯。
• 2'-O-modified nucleosides and phosphoramidites
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US05914396A1

  公开（公告）日：1999-06-22

  2'-O-Modified nucleosides, nucleotides, and oligonucleotides. These 2'-O-modified oligonucleotides are resistant to nuclease digestion and can effectively hybridize to a complementary polynucleotide.

  2'-O-修饰核苷、核苷酸和寡核苷酸。这些2'-O修饰的寡核苷酸能够抵抗核酸酶消化，能够有效地与互补的多核苷酸杂交。
• Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：EP1223173A2

  公开（公告）日：2002-07-17

  Novel 2'-O-alkyl guanosine compounds and analogs thereof are provided. Processes for the preparation of 2'-O-alkyl guanosine and analogs thereof are also provided. Processes for preparing 2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites are also provided. Methods for the use of oligonucleotides comprising 2'-O-alkyl guanosine are also provided.

  提供了新型 2'-O- 烷基鸟苷化合物及其类似物。还提供了制备 2'-O- 烷基鸟苷及其类似物的工艺。还提供了制备 2'-O 烷基鸟苷、尿苷、胞苷和 2,6-二氨基嘌呤 3'-O 磷酰胺的工艺。还提供了使用包含 2'-O- 烷基鸟苷的寡核苷酸的方法。
• ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 PRE-MRNA
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3998108A1

  公开（公告）日：2022-05-18

  The present invention aims at establishing a novel therapy for facioscapulohumeral muscular dystrophy. An oligonucleotide or a pharmaceutically acceptable salt thereof, wherein the oligonucleotide comprises an oligonucleotide of 15-30 bases consisting of a nucleotide sequence complementary to the region of nucleotide Nos. 502-556 or 578-612 of DUX4-fl mRNA consisting of the nucleotide sequence as shown in SEQ ID NO: 1; the 5' and/or 3' end of the oligonucleotide may be chemically modified; and the oligonucleotide is capable of switching the splice form of the DUX4 gene from DUX4-fl to DUX4-s. A pharmaceutical drug comprising the above oligonucleotide or a pharmaceutically acceptable salt thereof (e.g. therapeutic for facioscapulohumeral muscular dystrophy).

  本发明的目的是建立一种治疗面肱骨肌营养不良症的新型疗法。 一种寡核苷酸或其药学上可接受的盐，其中寡核苷酸包括由与 DUX4-fl mRNA 的核苷酸 Nos.寡核苷酸的 5'端和/或 3'端可进行化学修饰；并且寡核苷酸能够将 DUX4 基因的剪接形式从 DUX4-fl 转换为 DUX4-s。一种包含上述寡核苷酸或其药学上可接受的盐的药物（如治疗面肱骨肌营养不良症）。
• GALNAC-OLIGONUCLEOTIDE CONJUGATE FOR LIVER-TARGETED DELIVERY USE, AND METHOD FOR PRODUCING SAME
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP4029520A1

  公开（公告）日：2022-07-20

  The present invention provides a conjugate of an oligonucleotide having a nucleic acid sequence expected to have a pharmacological effect in hepatic parenchymal cells with a biantennary GalNAc unit, or a pharmaceutically acceptable salt thereof, and a medicament or the like containing the same as an active component.

  本发明提供了一种寡核苷酸的共轭物，该寡核苷酸具有可望在肝实质细胞中产生药理作用的核酸序列，带有一个双年基 GalNAc 单元，或其药学上可接受的盐，以及一种含有相同的寡核苷酸作为活性成分的药物或类似物。